Active Infection & Immunity Public Health & Healthcare

Trained immunity: using controlled human infection to study non-specific beneficial effects of vaccination

In plain English

AI plain-English summary

Vaccines can make the immune system better at fighting off infections they were not designed to target. This project will use controlled human infection—deliberately exposing volunteers to a pathogen—to study how and why this happens. Most vaccines are designed to protect against a single disease, but evidence suggests they sometimes have broader, non-specific benefits. For example, some vaccines reduce deaths from unrelated infections. The mechanisms behind this “trained immunity” remain poorly understood. This research aims to fill that gap by examining how vaccination and infection alter the immune system’s baseline responsiveness to a range of clinically significant pathogens, including *Streptococcus pneumoniae*, tuberculosis, and respiratory viruses such as RSV and SARS. If successful, the work could lead to new adjuvant formulations that deliberately trigger broad immune benefits, and to optimised vaccine schedules that maximise these effects. That would improve how vaccines are designed and deployed globally, potentially reducing the burden of infectious diseases beyond the target pathogen. The project is fundamental science with clear translational potential—it seeks a mechanistic understanding of a real-world observation that could reshape vaccination strategy.

View original technical description
This is an exciting opportunity to work in vaccine development at LSTM. You will be integrated into a dynamic team with a diverse research portfolio, supported by strategic collaborations with world-leading academic (Oxford) and industrial institutions. This project will work towards improving our understanding of how vaccination can confer non-specific beneficial effects. We will work to understand how favourable immune responses may be generated with both specific and non-specific beneficial impact - potentially leading to the development of novel adjuvant formulations and the optimisation of vaccine scheduling. We will study a variety of bacterial and viral pathogens of clinical significance, including Streptococcus pneumoniae, Mycobacterium tuberculosis, Salmonella enterica, SARS, MERS, and RSV. Projects will utilise ex vivo human models of infection, advanced analytical techniques (flow cytometry and confocal microscopy), and systems biology to assess the immunomodulatory impact of controlled human infection and vaccination. Projects will be tailored to the candidate and provide opportunity for industry training and overseas placement.

View the original record at the funder ↗

Related Research

Grants with similar aims, by meaning.

Novel immunomodulatory therapeutic strategies to target intracellular pathogens
Harnessing the power of T-cell responses to control future pandemics
Novel vaccines for major animal virus infections in developing countries
An 'unconventional' approach to the COVID 19 pandemic: the role of T cells in virus recognition
Human and Veterinary Vaccinology.

Original classification

Studentship

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.